Kadcyla™ (ado-trastuzumab emtansine)
Kadcyla (formerly referred to as T-DM1) consists of our proprietary DM1 cancer-killing agent attached to the HER2-binding antibody, trastuzumab, developed by Genentech (a member of the Roche Group) using our linker and methods of attachment.
Kadcyla™ Marketing Status
The US FDA granted marketing approval of Kadcyla for the treatment of people with HER2-positive metastatic breast cancer who have received prior treatment with Herceptin® (trastuzumab) and a taxane chemotherapy.
Genentech is the marketer of Kadcyla™ in the US – please refer to www.kadcyla.com for more information including complete prescribing information.
Marketing applications for Kadcyla are under review in Europe and Japan.
Development of Kadcyla for Additional Indications
Genentech/Roche have a number of clinical trials underway or planned to assess Kadcyla for additional uses. An update on the status of key trials is typically provided in our quarterly financial releases.
Herceptin® is a registered trademark of Genentech. Kadcyla™ is a trademark of Genentech.
Back to Pipeline
Last updated February 22, 2013